| Today’s Big NewsNov 2, 2023 |
| By Eric Sagonowsky,Fraiser Kansteiner Ever since Novo Nordisk won FDA approval for its GLP-1 weight-loss med Wegovy more than 2 years ago, analysts and investors have been keeping a close eye on the blockbuster drug launch. Now, Novo's third-quarter financial results bring the situation into clearer focus. |
|
|
|
By Max Bayer Moderna CEO Stéphane Bancel suggested that partnerships could be on the horizon depending on future sales figures. The company has built a largely wholly-owned pipeline thanks to revenue from the initial launch of its COVID vaccine. |
By Conor Hale Inari Medical has signed on to a $415 million deal to acquire LimFlow, just weeks after the company received FDA approval for its minimally invasive approach to re-establish oxygenated blood flow in the legs of people potentially facing amputation. |
By Angus Liu As strong demand continues to push Mounjaro sales to new highs, Eli Lilly CEO David Ricks said the company is "not done with" manufacturing expansions. |
|
Thursday, November 9, 2023 | 11am ET / 8am PT Navigating the U.S. regulatory landscape for the use of high-purity alcohols in biologic development and manufacturing processes is crucial for maintaining product quality and patient safety. However, biomanufacturers often face significant challenges. Join us to gain key guidance from industry experts and learn important best practices. Register now.
|
|
By Conor Hale The startup aims to provide a view into the workings of tissue and chart out cellular maps for a better understanding of organ function and disease. |
By Annalee Armstrong Eli Lilly is in an “all of the above mode” in obesity, with the research teams moving as fast as possible to advance an oral candidate and build a portfolio of complimentary treatments. |
By Zoey Becker BioMarin lured Genentech's CEO Alexander Hardy to take over upon Jean-Jacques Bienaimé's upcoming retirement after 18 years at the helm. |
By Annalee Armstrong After securing the first-ever approval for an oral microbiome therapy in April, Seres Therapeutics is facing some tough choices, resulting in a restructuring that will claim 41% of staff. |
By Kevin Dunleavy After gaining FDA approval for its high-dose Eylea, Regeneron racked up $43 million in sales in the U.S. over the final six weeks of the third quarter for the new formulation. Regeneron and partner Bayer are battling Roche's Vabysmo in the treatment of multiple eye diseases. |
By James Waldron Rani Therapeutics and Sangamo Therapeutics have become the latest biotechs to significantly shrink their workforces in order to eke out cash for another year. |
By Annalee Armstrong Locanabio will close up shop by the end of the year as a tough market for biotechs claims another company that had been working on developing RNA medicines for rare diseases such as Duchenne muscular dystrophy. |
Fierce podcastsDon’t miss an episode |
| In this episode of “The Top Line,” we delve into the FDA's controversial approval of Aduhelm, a drug for Alzheimer's disease, despite an independent advisory committee's resounding rejection. The decision has sparked questions about potential bias within the regulatory body. |
|
|---|
|
|
|
Thursday, November 16, 2023 | 1pm ET / 10am PT Genomics is transforming drug discovery, but finding and recruiting the right patients for targeted-therapies remains a challenge. Join us to discover how incorporating genetic counseling and genetic services can unlock larger, more diverse and better qualified patient populations for your clinical trials. Register now.
|
|
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperUncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| WhitepaperUncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
| |
|
